{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064531","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.309130+00:00","generated_at":"2026-05-22T12:46:25.807128+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Q1 2025 net loss $32.1M; cash $103.1M funds ops into Q2 2026","bullets":["Cash, cash equivalents, restricted cash and marketable securities of $103.1M as of March 31, 2025.","Net loss of $32.1M ($0.42 per share) vs. $31.4M ($0.42) in Q1 2024; R&D expense $28.8M (+5% YoY).","PRT3789 monotherapy and docetaxel combo dose escalation complete; Phase 2 data expected H2 2025.","PRT7732 Phase 1 advancing in 5th cohort at 60 mg once daily; initial data anticipated H2 2025.","KAT6A degrader program targeting candidate nomination in Q2 2025 and IND in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064531","json":"https://secwatch.observer/filing/0000950170-25-064531.json","markdown":"https://secwatch.observer/filing/0000950170-25-064531.md","text":"https://secwatch.observer/filing/0000950170-25-064531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/0000950170-25-064531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/prld-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:46:25.807128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}